在研药物
Investigational drugs are compounds that have been approved for testing in clinical trials. They have verified structure, manufacturing process, and quality control protocols as well as passed preliminary animal studies. Clinical trials will check if potential drugs work effectively and safely on humans. Compounds, successively passed all phases of clinical trials, can be submitted for FDA (or other pharmaceutical regulatory agency) approval to become a new drug.
The library of Investigational Drugs consists of 753 compounds that entered the first phase of clinical trials. All information about national clinical trial (NCT) numbers and annotated biological activity is also available.
Related terms: epidermal growth factor receptor, MET proto-oncogene, receptor tyrosine kinase, AKT serine/threonine kinase, aurora kinase A, mitogen-activated protein kinase
下载PDF文件
Highlights
Zorifertinib is a potent, orally active, central nervous system-penetrant, EGFR inhibitor with IC50= 0.5 nM
Presatovir (GS-5806) is a RSV fusion inhibitor.
Dapansutrile inhibits the NLRP3 inflammasome. It has anti-inflammatory, analgesic activity.
TAK-901 has antineoplastic activity. It is a multi-targeted aurora inhibitor (aurora A and B).
Product Features
Investigational Drugs Library is a set of 753 bioactive molecules for HTS/HCS programs.
Comprehensive documentation with structures, trivial names, synonyms, activity coefficient values, types of action on target and references to original literature.
NMR and LCMS validated purity.
All the compounds are available in stock for hit follow-up.
The library is continuously updated.
Product Details
Format: 10 - 100 µL of 10 mM DMSO stock solutions; dry powders (1 mg);
Container: 384-well microplates;
Storage: - 18 °C;
Shipping: Dry ice.
Utility
High throughput screening (HTS);
High content screening (HCS);
Cherry picking.
